Sino Biopharmaceutical has recently released its 2020 annual results, with total revenue of RMB23.647 billion, down 2.4% year on year, net profit attributable to the parent of RMB2.771 billion, up 0.3% year on year, net profit attributable to the parent of RMB3.114 billion excluding the impacts such as intangible assets amortization and convertible bond arising from the acquisition of Beijing Tide, decreased by 0.3% year on year, and R&D expenditure of RMB2.853 billion, accounting for 12.1% of the total revenue.
Anlotinib Sold Over RMB4 Billion
Sino Biopharmaceutical disclosed in a call meeting earlier that the sales of anlotinib in China were expected to reach RMB4-4.5 billion in 2020, which means that the blockbuster anlotinib contributed over 1/6 of the total revenue of RMB23.647 billion.
The Class 1 new drug anlotinib independently developed by Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical, was first approved in May 2018 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after at least two lines of systemic chemotherapy and was subsequently approved for the treatment of soft tissue sarcoma, small cell lung cancer (SCLC), and medullary thyroid cancer.
(Source: NMPA)
Anlotinib’s NSCLC indication was successfully included in the NRDL (National Reimbursement Drug List of China) in 2018; anlotinib was once again included in the NRDL in the new round of NRDL negotiations in 2020, with a price reduction by 37%, covering three indications: NSCLC, SCLC, and soft tissue sarcoma.
Chia Tai Tianqing is actively developing other indications for anlotinib, with a total of over 20 clinical trials underway. Among them, combination regimens of anlotinib and anti-PD-1/L1 drugs in development, which involve gastric cancer, liver cancer, and gastroesophageal junction adenocarcinoma, are already in Phase III clinical trials.
(Source: China Drug Clinical Trial Registration and Information Publicity Platform)
Which will be the Next Blockbuster?
Undoubtedly, anlotinib will be a powerful growth engine for Sino Biopharmaceutical in the next three to five years. Then, with the full implementation of China’s centralized drug-procurement program, which will be the next innovative drug to be marketed by Sino Biopharmaceutical? Which will be the next blockbuster following anlotinib?
Sino Biopharmaceutical has now over 100 innovative drug varieties in development, with two marketed, three applied for production, and 33 in clinical stages. If you are looking for a professional bio pharmaceutical company in China, then Pharmasources would be your best choice.
Innovative Drug Pipelines in Development by Sino Biopharmaceutical
(Source: Company announcements, Pharmcube, Zhongtai Securities Research Institute)
Among the three drugs applied for marketing, AK105 and TQ-Z2301 are not considered to be Sino Biopharmaceutical’s own innovative drugs. AK105 is an anti-PD-1 monoclonal antibody independently developed by Akeso, and Chia Tai Tianqing only has exclusive sales rights for AK105 in China. TQ-Z2301 is an adalimumab biosimilar. Only the recombinant human coagulation factor VIII for the treatment of Hemophilia A is considered to be Sino Biopharmaceutical’s own innovative drug and is expected to be approved for marketing this year, however, it is unlikely to become a blockbuster due to the restricted indication for the treatment of hemophilia A.Read More
(All Rights Reserved)